More on Amgen (AMGN): Q2 beats across the board on a 13% Y/Y jump in total revenue. Product sales growth was driven by strong performance across the portfolio. Xgeva sales total: $179M. For 2012, the company guides higher, now seeing an EPS of $6.20 to $6.35 on revenue of $16.9B to $17.2B. Street estimates are for earnings of $6.15 per share on $16.37B in revenue. Shares +4.4% AH.